ALXO — ALX Oncology Holdings Inc.

ALX Oncology Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• The company reported a strong quarter, bolstered by a successful financing round in February, which improved the balance sheet and positioned ALX for upcoming data milestones.
• Specific financial metrics were not disclosed in the transcript, but the emphasis was on a solid financial foundation to support ongoing clinical trials.

2. Strategic Updates and Business Highlights

• ALX Oncology presented promising data from their trials evaluating evorpacept (Evo) and zanidatamab in HER2-positive metastatic breast cancer at the ESMO Breast 2026 conference.
• Key findings indicated that CD47 expression is a predictive biomarker for durable clinical responses in heavily pretreated HER2-positive patients, with a 33% overall response rate and a median duration of response of 20 months.
• The ongoing ASPEN-09 Phase II trial for Evo in breast cancer is progressing well, with strong enrollment and expected interim data from about 80 patients by mid-2027.
• The ALX2004 EGFR-targeted ADC is also advancing, with dose escalation on track for an initial safety readout in the second half of 2026.

3. Forward Guidance and Outlook

• ALX Oncology aims to have both Evo and ALX2004 ready for registrational studies by the end of 2027.
• The company is optimistic about the potential market opportunity for Evo, estimating around 20,000 addressable patients in the U.S. and major European markets, translating to a market potential of $2 billion to $4 billion.

4. Bad News, Challenges, or Points of Concern

• The company acknowledged the high bar for accelerated approval based on single-arm trials, particularly for the combination of Evo and zanidatamab, which may complicate regulatory pathways.
• There is uncertainty regarding the optimal CD47 expression cutoff for patient selection, which could impact the effectiveness of future studies and market potential.
• The small sample sizes in current trials may limit the robustness of conclusions, and the company is cautious about making definitive statements regarding the use of CD47 as a companion diagnostic until more data is available.

5. Notable Q&A Insights

• Management indicated that a response rate above 30% in the upcoming ASPEN-09 data would be considered compelling, with a duration of response of over 6 months being favorable.
• Dr. Sara Hurvitz emphasized the potential for CD47 expression testing to become a companion diagnostic if validated, though it remains too early to confirm this.
• Questions highlighted the importance of understanding HER2 positivity and CD47 expression levels, with management noting that ongoing studies would clarify these metrics.
• The company is focused on ensuring that tissue adequacy and turnaround times do not become gating factors for enrollment in ASPEN-09, as the study currently enrolls patients irrespective of CD47 status.

Overall, ALX Oncology is navigating a promising trajectory with its clinical programs while being mindful of regulatory challenges and the need for robust data to support its strategic initiatives.